For instance, the MEK inhibitor cobimetinib was found to reduce Breg populations in tumor-draining lymph nodes (TDLNs) while preserving anti-tumor humoral immunity in a colorectal cancer model [27]. This evidence concerns the gene MAP2K7 and neoplasm.